Robyn Samuels
Corporate Officer/Principal at TFMG Associates LLC
Network origin in Robyn Samuels first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Extinct | Biotechnology | 10 | |
Synageva BioPharma Corp. /Old/
 Synageva BioPharma Corp. /Old/ BiotechnologyHealth Technology Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™.
7
| Extinct | Biotechnology | 7 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Robyn Samuels via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| HERON THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer Chief Operating Officer | |
Agouron Pharmaceuticals LLC
 Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| Putnam Investment Funds | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
| VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Public Communications Contact | |
| ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | General Counsel Chief Tech/Sci/R&D Officer | |
Milbank LLP
 Milbank LLP Miscellaneous Commercial ServicesCommercial Services Milbank LLP provides legal services. It serves corporate, finance, financial restructuring, litigation and arbitration, securities, capital markets, trusts, estates, and exempt organizations, and tax markets. The company was founded in 1866 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| ACADIA PHARMACEUTICALS INC. | Pharmaceuticals: Major | Chief Executive Officer Chairman | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | General Counsel Sales & Marketing Corporate Officer/Principal Chief Operating Officer General Counsel | |
| BELLICUM PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
FORMA Therapeutics, Inc.
 FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Biotechnology | Chairman | |
| SHIRE | Pharmaceuticals: Major | Investor Relations Contact | |
| AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member | |
| FORMA THERAPEUTICS HOLDINGS, INC. | Pharmaceuticals: Major | Chairman | |
| CENTREXION THERAPEUTICS CORPORATION | Pharmaceuticals: Major | Director/Board Member | |
| COGENT BIOSCIENCES, INC. | Biotechnology | Director of Finance/CFO | |
| Stanford University | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree | |
Leerink Partners LLC
 Leerink Partners LLC Investment Banks/BrokersFinance Leerink Partners LLC is a full-service brokerage and investment banking firm headquartered in Boston, Massachusetts. The firm was founded by Jeffrey Leerink in 1995 and formerly known as SVB Securities LLC. They rebranded as Leerink Partners in 2023. The firm is a subsidiary of SVB Securities LLC. Leerink Partners provides institutional sales, equity research, institutional trading, and corporate finance and asset management services to the healthcare and technology industries. They offer superior execution capabilities in common stock, convertibles and derivatives with a singular focus on healthcare and a knowledge-led approach. | Investment Banks/Brokers | Analyst-Equity | |
| ATEC, INC. | Engineering & Construction | Director/Board Member | |
| Syracuse University | College/University | Undergraduate Degree | |
| Southern Nazarene University | College/University | Undergraduate Degree | |
| University of Wisconsin | College/University | Undergraduate Degree | |
National Parks Conservation Association
 National Parks Conservation Association Miscellaneous Commercial ServicesCommercial Services The National Parks Conservation Association is a nonpartisan organization that has been working to safeguard national parks since 1919. The non-profit company is based in Washington. With over 1.6 million members and supporters, they aim to protect and preserve the most iconic and inspirational places in the country for future generations. The organization believes in engaging the next generation to ensure the protection of national parks, which is why they launched the Next Generation Advisory Council. The CEO of the American company is Theresa Pierno. | Miscellaneous Commercial Services | Director/Board Member | |
Alphatec Spine, Inc.
 Alphatec Spine, Inc. Medical SpecialtiesHealth Technology Alphatec Spine, Inc. is focused on the design, development, manufacturing, and marketing of products for the surgical treatment of spine disorders, with a focus on treating condition affecting the aging spine. The firms product portfolio and pipeline include spinal disorder products and systems. The company was founded in 1990 and is headquartered in Carlsbad, CA. | Medical Specialties | Director/Board Member | |
Apple Tree venture Managemnet Llc//vc
 Apple Tree venture Managemnet Llc//vc Investment ManagersFinance Apple Tree venture Managemnet LLC (Apple Tree Partners) is a venture capital firm founded by Seth Harrison in 1999. The firm is headquartered in New York with an additional offices in London, San Francisco and Cambridge. | Investment Managers | Public Communications Contact | |
Ardea Biosciences, Inc.
 Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ardea Biosciences, Inc. is a biotechnology company which is focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company was founded in January 1994 and is headquartered in Wilmington, DE. | Pharmaceuticals: Major | Founder Chief Operating Officer | |
| D'Amore-Mckim School of Business | College/University | Masters Business Admin | |
| SYROS PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member Chairman | |
| KINIKSA PHARMACEUTICALS, LTD. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Lord Abbett Credit Opportunities Fund
 Lord Abbett Credit Opportunities Fund Investment Trusts/Mutual FundsMiscellaneous Lord Abbett Credit Opportunities Fund is a closed-end management investment company that continuously offers its common shares and is operated as an interval fund. The company was founded on September 18, 2018 and is Headquartered in Jersey City, NJ. | Investment Trusts/Mutual Funds | Chairman | |
| Vanderbilt Law School | College/University | Graduate Degree | |
| VOYAGER THERAPEUTICS, INC. | Biotechnology | Investor Relations Contact | |
Oncxerna Therapeutics, Inc.
 Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director of Finance/CFO | |
| Harvard Law School | College/University | Graduate Degree | |
| CRANE COMPANY | Aerospace & Defense | Director/Board Member | |
| CRANE NXT, CO. | Industrial Machinery | Director/Board Member | |
Lord Abbett Special Situations Income Fund
 Lord Abbett Special Situations Income Fund Investment Trusts/Mutual FundsMiscellaneous Lord Abbett Special Situations Income Fund operates as an interval fund. It is a non-diversified, closed-end management investment firm. Its investment objective is total return and capital appreciation. The company was founded in 2021 and is headquartered in Jersey City, NJ. | Investment Trusts/Mutual Funds | Chairman | |
Lord Abbett Enhanced Floating Rate Fund
 Lord Abbett Enhanced Floating Rate Fund Investment Trusts/Mutual FundsMiscellaneous Lord Abbett Enhanced Floating Rate Fund operates as an organized, non-diversified, closed-end management investment company that offers its shares and is operated as an interval fund. Its investment objective is to seek a high level of current income. The company is headquartered in Jersey City, NJ. | Investment Trusts/Mutual Funds | Chairman |
Statistics
International
| United States | 46 |
| Ireland | 2 |
Sectoral
| Health Technology | 26 |
| Consumer Services | 8 |
| Miscellaneous | 5 |
| Finance | 5 |
| Commercial Services | 4 |
Operational
| Director/Board Member | 124 |
| Independent Dir/Board Member | 42 |
| Corporate Officer/Principal | 40 |
| Chairman | 20 |
| Undergraduate Degree | 14 |
Most connected contacts
| Insiders | |
|---|---|
| Srini Akkaraju Akkaraju | 54 |
| James Tullis | 32 |
| Thomas Tisch | 27 |
| Peter Wirth | 15 |
| Matthew Osborne | 14 |
| Barry Quart | 13 |
| Stephen Biggar | 12 |
| Stephen Davis | 11 |
| John Taylor | 11 |
| Anthony Quinn | 11 |
| Eric Grinstead | 9 |
| Radhika Tripuraneni | 7 |
| Brian Conner | 6 |
| Stephen Andre | 6 |
| Mark C. Leavitt | 4 |
- Stock Market
- Insiders
- Robyn Samuels
- Company connections
